

# Alberto Orfao

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2398081/publications.pdf>

Version: 2024-02-01

238  
papers

16,895  
citations

18465

62  
h-index

18115

120  
g-index

244  
all docs

244  
docs citations

244  
times ranked

16236  
citing authors

#	ARTICLE	IF	CITATIONS
1	Flow cytometric analysis of myelodysplasia: Pre-analytical and technical issues” Recommendations from the European <scp>LeukemiaNet</scp>. Cytometry Part B - Clinical Cytometry, 2023, 104, 15-26.	0.7	16
2	Clinical application of flow cytometry in patients with unexplained cytopenia and suspected myelodysplastic syndrome: A report of the European <scp>LeukemiaNet</scp> International <scp>MDS&Flow</scp> Cytometry Working Group. Cytometry Part B - Clinical Cytometry, 2023, 104, 77-86.	0.7	18
3	Frequency and prognostic impact of blood-circulating tumor mast cells in mastocytosis. Blood, 2022, 139, 572-583.	0.6	8
4	Interlaboratory Analytical Validation of a Next-Generation Sequencing Strategy for Clonotypic Assessment and Minimal Residual Disease Monitoring in Multiple Myeloma. Archives of Pathology and Laboratory Medicine, 2022, 146, 862-871.	1.2	7
5	High-Sensitive TRBC1-Based Flow Cytometric Assessment of T-Cell Clonality in T $\pm$ L $\pm$ -Large Granular Lymphocytic Leukemia. Cancers, 2022, 14, 408.	1.7	10
6	Deciphering Biomarkers for Leptomeningeal Metastasis in Malignant Hemopathies (Lymphoma/Leukemia) Patients by Comprehensive Multipronged Proteomics Characterization of Cerebrospinal Fluid. Cancers, 2022, 14, 449.	1.7	4
7	Age and Primary Vaccination Background Influence the Plasma Cell Response to Pertussis Booster Vaccination. Vaccines, 2022, 10, 136.	2.1	11
8	Impact of Pre-Analytical and Analytical Variables Associated with Sample Preparation on Flow Cytometric Stainings Obtained with EuroFlow Panels. Cancers, 2022, 14, 473.	1.7	3
9	Immunophenotypic Analysis of Acute Megakaryoblastic Leukemia: A EuroFlow Study. Cancers, 2022, 14, 1583.	1.7	11
10	Mastocytosis presenting with mast cell&mediator release&associated symptoms elicited by cyclo oxygenase inhibitors: prevalence, clinical, and laboratory features. Clinical and Translational Allergy, 2022, 12, e12132.	1.4	11
11	Standards of Genetic Testing in the Diagnosis and Prognostication of Systemic Mastocytosis in 2022: Recommendations of the EU-US Cooperative Group. Journal of Allergy and Clinical Immunology: in Practice, 2022, 10, 1953-1963.	2.0	20
12	Personalized Management Strategies in Mast Cell Disorders: ECNM-AIM User&TM’s Guide for Daily Clinical Practice. Journal of Allergy and Clinical Immunology: in Practice, 2022, 10, 1999-2012.e6.	2.0	35
13	Flow cytometric minimal residual disease assessment in B&cell precursor acute lymphoblastic leukaemia patients treated with CD19&targeted therapies &” a EuroFlow study. British Journal of Haematology, 2022, 197, 76-81.	1.2	8
14	Clinical impact and proposed application of molecular markers, genetic variants, and cytogenetic analysis in mast cell neoplasms: Status 2022. Journal of Allergy and Clinical Immunology, 2022, 149, 1855-1865.	1.5	19
15	Quality Assessment of a Large Multi-Center Flow Cytometric Dataset of Acute Myeloid Leukemia Patients&” A EuroFlow Study. Cancers, 2022, 14, 2011.	1.7	3
16	Comprehensive Analysis of Acquired Genetic Variants and Their Prognostic Impact in Systemic Mastocytosis. Cancers, 2022, 14, 2487.	1.7	4
17	Altered innate immune profile in blood of systemic mastocytosis patients. Clinical and Translational Allergy, 2022, 12, .	1.4	4
18	Bone Marrow Stromal Cell Regeneration Profile in Treated B-Cell Precursor Acute Lymphoblastic Leukemia Patients: Association with MRD Status and Patient Outcome. Cancers, 2022, 14, 3088.	1.7	3

#	ARTICLE	IF	CITATIONS
19	Circulating Tumor Cells for the Staging of Patients With Newly Diagnosed Transplant-Eligible Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2022, 40, 3151-3161.	0.8	40
20	Genomic profiling of sporadic liver metastatic colorectal cancer. <i>Seminars in Cancer Biology</i> , 2021, 71, 98-108.	4.3	8
21	Chemotherapy or allogeneic transplantation in high-risk Philadelphia chromosome-negative adult lymphoblastic leukemia. <i>Blood</i> , 2021, 137, 1879-1894.	0.6	48
22	Standardised immunophenotypic analysis of myeloperoxidase in acute leukaemia. <i>British Journal of Haematology</i> , 2021, 193, 922-927.	1.2	6
23	Automated identification of leukocyte subsets improves standardization of database-guided expert-supervised diagnostic orientation in acute leukemia: a EuroFlow study. <i>Modern Pathology</i> , 2021, 34, 59-69.	2.9	15
24	Tumor cell and immune cell profiles in primary human glioblastoma: Impact on patient outcome. <i>Brain Pathology</i> , 2021, 31, 365-380.	2.1	27
25	Genome-wide association study identifies novel susceptibility loci for KIT D816V positive mastocytosis. <i>American Journal of Human Genetics</i> , 2021, 108, 284-294.	2.6	12
26	Impact of measurable residual disease by decentralized flow cytometry: a PETHEMA real-world study in 1076 patients with acute myeloid leukemia. <i>Leukemia</i> , 2021, 35, 2358-2370.	3.3	31
27	Precision Medicine in Hematology 2021: Definitions, Tools, Perspectives, and Open Questions. <i>HemaSphere</i> , 2021, 5, e536.	1.2	11
28	Minimal residual disease negativity by next-generation flow cytometry is associated with improved organ response in AL amyloidosis. <i>Blood Cancer Journal</i> , 2021, 11, 34.	2.8	39
29	Monocyte Subsets and Serum Inflammatory and Bone-Associated Markers in Monoclonal Gammopathy of Undetermined Significance and Multiple Myeloma. <i>Cancers</i> , 2021, 13, 1454.	1.7	10
30	Dynamic Intracellular Metabolic Cell Signaling Profiles During Ag-Dependent B-Cell Differentiation. <i>Frontiers in Immunology</i> , 2021, 12, 637832.	2.2	4
31	Proposed global prognostic score for systemic mastocytosis: a retrospective prognostic modelling study. <i>Lancet Haematology</i> , 2021, 8, e194-e204.	2.2	39
32	B-Cell Regeneration Profile and Minimal Residual Disease Status in Bone Marrow of Treated Multiple Myeloma Patients. <i>Cancers</i> , 2021, 13, 1704.	1.7	6
33	COVID-19 infection in patients with mast cell disorders including mastocytosis does not impact mast cell activation symptoms. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 2083-2086.	2.0	16
34	Tracking the Antibody Immunome in Sporadic Colorectal Cancer by Using Antigen Self-Assembled Protein Arrays. <i>Cancers</i> , 2021, 13, 2718.	1.7	9
35	GlcNAc is a mast-cell chromatin-remodeling oncometabolite that promotes systemic mastocytosis aggressiveness. <i>Blood</i> , 2021, 138, 1590-1602.	0.6	4
36	Analysis of minimal residual disease in bone marrow by NGF and in peripheral blood by mass spectrometry in newly diagnosed multiple myeloma patients enrolled in the GEM2012MENOS65 clinical trial. <i>Journal of Clinical Oncology</i> , 2021, 39, 8010-8010.	0.8	6

#	ARTICLE	IF	CITATIONS
37	Strategy to prevent epitope masking in CAR.CD19+ B-cell leukemia blasts. , 2021, 9, e001514.		10
38	Highly Sensitive Flow Cytometry Allows Monitoring of Changes in Circulating Immune Cells in Blood After Tdap Booster Vaccination. <i>Frontiers in Immunology</i> , 2021, 12, 666953.	2.2	17
39	Selecting the Right Criteria and Proper Classification to Diagnose Mast Cell Activation Syndromes: A Critical Review. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 3918-3928.	2.0	33
40	Improved SÃ©zary cell detection and novel insights into immunophenotypic and molecular heterogeneity in SÃ©zary syndrome. <i>Blood</i> , 2021, 138, 2539-2554.	0.6	28
41	Minimal Residual Disease in Myeloma: Application for Clinical Care and New Drug Registration. <i>Clinical Cancer Research</i> , 2021, 27, 5195-5212.	3.2	26
42	Clinicobiological Characteristics and Outcomes of Patients with T-Cell Large Granular Lymphocytic Leukemia and Chronic Lymphoproliferative Disorder of Natural Killer Cells from a Single Institution. <i>Cancers</i> , 2021, 13, 3900.	1.7	12
43	Outcomes and prognostic factors of adults with refractory or relapsed Tâ€cell acute lymphoblastic leukemia included in measurable residual diseaseâ€oriented trials. <i>Hematological Oncology</i> , 2021, 39, 529-538.	0.8	3
44	Anti-TRBC1 Antibody-Based Flow Cytometric Detection of T-Cell Clonality: Standardization of Sample Preparation and Diagnostic Implementation. <i>Cancers</i> , 2021, 13, 4379.	1.7	17
45	Prognostic heterogeneity of adult Bâ€cell precursor acute lymphoblastic leukaemia patients with t(1;19)(q23;p13)/TCF3â€PBX1 treated with measurable residual diseaseâ€oriented protocols. <i>British Journal of Haematology</i> , 2021, , .	1.2	2
46	Flow Cytometry Immunophenotyping for Diagnostic Orientation and Classification of Pediatric Cancer Based on the EuroFlow Solid Tumor Orientation Tube (STOT). <i>Cancers</i> , 2021, 13, 4945.	1.7	5
47	Genomic Heterogeneity of Pancreatic Ductal Adenocarcinoma and Its Clinical Impact. <i>Cancers</i> , 2021, 13, 4451.	1.7	15
48	Reference Values to Assess Hemodilution and Warn of Potential False-Negative Minimal Residual Disease Results in Myeloma. <i>Cancers</i> , 2021, 13, 4924.	1.7	11
49	Pathogenic and diagnostic relevance of KIT in primary mast cell activation disorders. <i>Annals of Allergy, Asthma and Immunology</i> , 2021, 127, 427-434.	0.5	5
50	Monocytes carrying GFAP detect glioma, brain metastasis and ischaemic stroke, and predict glioblastoma survival. <i>Brain Communications</i> , 2021, 3, fcaa215.	1.5	11
51	Updated Diagnostic Criteria and Classification of Mast Cell Disorders: A Consensus Proposal. <i>HemaSphere</i> , 2021, 5, e646.	1.2	128
52	Overcoming Resistance to Immunotherapy in Advanced Cutaneous Squamous Cell Carcinoma. <i>Cancers</i> , 2021, 13, 5134.	1.7	8
53	The Hydropathy Index of the HCDR3 Region of the B-Cell Receptor Identifies Two Subgroups of IGHV-Mutated Chronic Lymphocytic Leukemia Patients With Distinct Outcome. <i>Frontiers in Oncology</i> , 2021, 11, 723722.	1.3	0
54	Circulating Tumor Cells (CTCs) in Smoldering and Active Multiple Myeloma (MM): Mechanism of Egression, Clinical Significance and Therapeutic Endpoints. <i>Blood</i> , 2021, 138, 76-76.	0.6	7

#	ARTICLE	IF	CITATIONS
55	Expert-independent classification of mature B-cell neoplasms using standardized flow cytometry: a multicentric study. <i>Blood Advances</i> , 2021, , .	2.5	9
56	Deepening into Intracellular Signaling Landscape through Integrative Spatial Proteomics and Transcriptomics in a Lymphoma Model. <i>Biomolecules</i> , 2021, 11, 1776.	1.8	8
57	Genomic Data Improves Prognostic Stratification in Adult T-Cell Acute Lymphoblastic Leukemia Patients Enrolled in Measurable Residual Disease-Oriented Trials. <i>Blood</i> , 2021, 138, 3486-3486.	0.6	2
58	Whole-Exome Sequencing Reveals Recurrent but Heterogeneous Mutational Profiles in Sporadic WHO Grade 1 Meningiomas. <i>Frontiers in Oncology</i> , 2021, 11, 740782.	1.3	5
59	Transcriptional profiling of circulating tumor cells in multiple myeloma: a new model to understand disease dissemination. <i>Leukemia</i> , 2020, 34, 589-603.	3.3	41
60	High frequency of chronic lymphocytic leukemia-like low-count monoclonal B-cell lymphocytosis in Japanese descendants living in Brazil. <i>Haematologica</i> , 2020, 105, e298-e301.	1.7	7
61	Measurable Residual Disease by Next-Generation Flow Cytometry in Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2020, 38, 784-792.	0.8	175
62	STAT3 and STAT5B Mutations in T/NK-Cell Chronic Lymphoproliferative Disorders of Large Granular Lymphocytes (LGL): Association with Disease Features. <i>Cancers</i> , 2020, 12, 3508.	1.7	34
63	Comparison of next-generation sequencing (NGS) and next-generation flow (NGF) for minimal residual disease (MRD) assessment in multiple myeloma. <i>Blood Cancer Journal</i> , 2020, 10, 108.	2.8	60
64	Mast cells as a unique hematopoietic lineage and cell system: From Paul Ehrlich's visions to precision medicine concepts. <i>Theranostics</i> , 2020, 10, 10743-10768.	4.6	107
65	Improved Standardization of Flow Cytometry Diagnostic Screening of Primary Immunodeficiency by Software-Based Automated Gating. <i>Frontiers in Immunology</i> , 2020, 11, 584646.	2.2	11
66	Circulating tumor cells for comprehensive and multiregional non-invasive genetic characterization of multiple myeloma. <i>Leukemia</i> , 2020, 34, 3007-3018.	3.3	26
67	Detection of Circulating Tumor Plasma Cells in Monoclonal Gammopathies: Methods, Pathogenic Role, and Clinical Implications. <i>Cancers</i> , 2020, 12, 1499.	1.7	19
68	Risk and management of patients with mastocytosis and MCAS in the SARS-CoV-2 (COVID-19) pandemic: Expert opinions. <i>Journal of Allergy and Clinical Immunology</i> , 2020, 146, 300-306.	1.5	23
69	Age Distribution of Multiple Functionally Relevant Subsets of CD4+ T Cells in Human Blood Using a Standardized and Validated 14-Color EuroFlow Immune Monitoring Tube. <i>Frontiers in Immunology</i> , 2020, 11, 166.	2.2	39
70	Upgraded Standardized Minimal Residual Disease Detection by Next-Generation Sequencing in Multiple Myeloma. <i>Journal of Molecular Diagnostics</i> , 2020, 22, 679-684.	1.2	11
71	A pediatric regimen for adolescents and young adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: Results of the ALLRE08 PETHEMA trial. <i>Cancer Medicine</i> , 2020, 9, 2317-2329.	1.3	13
72	Heterogeneous EGFR, CDK4, MDM4, and PDGFRA Gene Expression Profiles in Primary GBM: No Association with Patient Survival. <i>Cancers</i> , 2020, 12, 231.	1.7	13

#	ARTICLE	IF	CITATIONS
73	EuroFlow Standardized Approach to Diagnostic Immunophenotyping of Severe PID in Newborns and Young Children. <i>Frontiers in Immunology</i> , 2020, 11, 371.	2.2	17
74	Minimal Residual Disease Detection by Next-Generation Sequencing in Multiple Myeloma: A Comparison With Real-Time Quantitative PCR. <i>Frontiers in Oncology</i> , 2020, 10, 611021.	1.3	3
75	Dissection of the Pre-Germinal Center B-Cell Maturation Pathway in Common Variable Immunodeficiency Based on Standardized Flow Cytometric EuroFlow Tools. <i>Frontiers in Immunology</i> , 2020, 11, 603972.	2.2	13
76	Biological and clinical significance of dysplastic hematopoiesis in patients with newly diagnosed multiple myeloma. <i>Blood</i> , 2020, 135, 2375-2387.	0.6	24
77	Detection of circulating tumor cells in blood of pancreatic ductal adenocarcinoma patients. <i>Cancer Drug Resistance (Alhambra, Calif )</i> , 2020, 3, 83-97.	0.9	3
78	Outcome of Adults with Relapsed T-Cell Acute Lymphoblastic Leukemia (T-ALL) Included in Minimal Residual Disease (MRD)-Oriented Trials. <i>Blood</i> , 2020, 136, 6-7.	0.6	0
79	Molecular profiling refines minimal residual disease-based prognostic assessment in adults with Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia. <i>Genes Chromosomes and Cancer</i> , 2019, 58, 815-819.	1.5	6
80	Complete Multilineage CD4 Expression Defect Associated With Warts Due to an Inherited Homozygous CD4 Gene Mutation. <i>Frontiers in Immunology</i> , 2019, 10, 2502.	2.2	15
81	Frequency of clonal mast cell diseases among patients presenting with anaphylaxis: A prospective study in 178 patients from 5 tertiary centers in Spain. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2019, 7, 2924-2926.e1.	2.0	7
82	International prognostic scoring system for mastocytosis (IPSM): a retrospective cohort study. <i>Lancet Haematology</i> , 2019, 6, e638-e649.	2.2	101
83	Immunophenotypic dissection of normal hematopoiesis. <i>Journal of Immunological Methods</i> , 2019, 475, 112684.	0.6	38
84	Comments on EuroFlow standard operating procedures for instrument setup and compensation for BD FACS Canto II, Navios and BD FACS Lyric instruments. <i>Journal of Immunological Methods</i> , 2019, 475, 112680.	0.6	24
85	Guidelines for the use of flow cytometry and cell sorting in immunological studies (second edition). <i>European Journal of Immunology</i> , 2019, 49, 1457-1973.	1.6	766
86	MARS: Mutation-Adjusted Risk Score for Advanced Systemic Mastocytosis. <i>Journal of Clinical Oncology</i> , 2019, 37, 2846-2856.	0.8	82
87	EuroFlow Lymphoid Screening Tube (LST) data base for automated identification of blood lymphocyte subsets. <i>Journal of Immunological Methods</i> , 2019, 475, 112662.	0.6	35
88	Bone Marrow Mast Cell Antibody-Targetable Cell Surface Protein Expression Profiles in Systemic Mastocytosis. <i>International Journal of Molecular Sciences</i> , 2019, 20, 552.	1.8	9
89	Standardized Minimal Residual Disease Detection by Next-Generation Sequencing in Multiple Myeloma. <i>Frontiers in Oncology</i> , 2019, 9, 449.	1.3	25
90	Fluorochrome choices for multi-color flow cytometry. <i>Journal of Immunological Methods</i> , 2019, 475, 112618.	0.6	43

#	ARTICLE	IF	CITATIONS
91	EuroFlow-Based Flowcytometric Diagnostic Screening and Classification of Primary Immunodeficiencies of the Lymphoid System. <i>Frontiers in Immunology</i> , 2019, 10, 1271.	2.2	43
92	Frequency and prognostic impact of KIT and other genetic variants in indolent systemic mastocytosis. <i>Blood</i> , 2019, 134, 456-468.	0.6	44
93	Distribution of subsets of blood monocytic cells throughout life. <i>Journal of Allergy and Clinical Immunology</i> , 2019, 144, 320-323.e6.	1.5	32
94	The poor prognosis of low hypodiploidy in adults with B-cell precursor acute lymphoblastic leukaemia is restricted to older adults and elderly patients. <i>British Journal of Haematology</i> , 2019, 186, 263-268.	1.2	6
95	Maturation-associated gene expression profiles during normal human bone marrow erythropoiesis. <i>Cell Death Discovery</i> , 2019, 5, 69.	2.0	29
96	Defects in memory B-cell and plasma cell subsets expressing different immunoglobulin-subclasses in patients with CVID and immunoglobulin subclass deficiencies. <i>Journal of Allergy and Clinical Immunology</i> , 2019, 144, 809-824.	1.5	55
97	Proposed Diagnostic Algorithm for Patients with Suspected Mast Cell Activation Syndrome. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2019, 7, 1125-1133.e1.	2.0	150
98	Blood monitoring of circulating tumor plasma cells by next generation flow in multiple myeloma after therapy. <i>Blood</i> , 2019, 134, 2218-2222.	0.6	66
99	EuroFlow and its activities: Introduction to the special EuroFlow issue of <i>The Journal of Immunological Methods</i> . <i>Journal of Immunological Methods</i> , 2019, 475, 112704.	0.6	2
100	Delineating Human B Cell Precursor Development With Genetically Identified PID Cases as a Model. <i>Frontiers in Immunology</i> , 2019, 10, 2680.	2.2	14
101	Flow cytometry for fast screening and automated risk assessment in systemic light-chain amyloidosis. <i>Leukemia</i> , 2019, 33, 1256-1267.	3.3	20
102	PERISCOPE: road towards effective control of pertussis. <i>Lancet Infectious Diseases</i> , The, 2019, 19, e179-e186.	4.6	67
103	Frequent issues and lessons learned from EuroFlow QA. <i>Journal of Immunological Methods</i> , 2019, 475, 112520.	0.6	26
104	Selection and validation of antibody clones against IgG and IgA subclasses in switched memory B-cells and plasma cells. <i>Journal of Immunological Methods</i> , 2019, 475, 112372.	0.6	17
105	How to make usage of the standardized EuroFlow 8-color protocols possible for instruments of different manufacturers. <i>Journal of Immunological Methods</i> , 2019, 475, 112388.	0.6	23
106	Differential expression of CD73, CD86 and CD304 in normal vs. leukemic B-cell precursors and their utility as stable minimal residual disease markers in childhood B-cell precursor acute lymphoblastic leukemia. <i>Journal of Immunological Methods</i> , 2019, 475, 112429.	0.6	40
107	Optimization and testing of dried antibody tube: The EuroFlow LST and PIDOT tubes as examples. <i>Journal of Immunological Methods</i> , 2019, 475, 112287.	0.6	29
108	Lot-to-lot stability of antibody reagents for flow cytometry. <i>Journal of Immunological Methods</i> , 2019, 475, 112294.	0.6	20



#	ARTICLE	IF	CITATIONS
109	The EuroFlow PID Orientation Tube for Flow Cytometric Diagnostic Screening of Primary Immunodeficiencies of the Lymphoid System. <i>Frontiers in Immunology</i> , 2019, 10, 246.	2.2	100
110	Richter transformation driven by Epstein-Barr virus reactivation during therapy-related immunosuppression in chronic lymphocytic leukaemia. <i>Journal of Pathology</i> , 2018, 245, 61-73.	2.1	24
111	Age-associated distribution of normal B-cell and plasma cell subsets in peripheral blood. <i>Journal of Allergy and Clinical Immunology</i> , 2018, 141, 2208-2219.e16.	1.5	217
112	Molecular detection of minimal residual disease in multiple myeloma. <i>British Journal of Haematology</i> , 2018, 181, 11-26.	1.2	39
113	Low-count monoclonal B-cell lymphocytosis persists after seven years of follow up and is associated with a poorer outcome. <i>Haematologica</i> , 2018, 103, 1198-1208.	1.7	34
114	Basophil-lineage commitment in acute promyelocytic leukemia predicts for severe bleeding after starting therapy. <i>Modern Pathology</i> , 2018, 31, 1318-1331.	2.9	9
115	Impact of somatic and germline mutations on the outcome of systemic mastocytosis. <i>Blood Advances</i> , 2018, 2, 2814-2828.	2.5	42
116	Residual normal B-cell profiles in monoclonal B-cell lymphocytosis versus chronic lymphocytic leukemia. <i>Leukemia</i> , 2018, 32, 2701-2705.	3.3	19
117	Prognostic stratification of adult primary glioblastoma multiforme patients based on their tumor gene amplification profiles. <i>Oncotarget</i> , 2018, 9, 28083-28102.	0.8	5
118	Introduction to the diagnosis and classification of monocytic-lineage leukemias by flow cytometry. <i>Cytometry Part B - Clinical Cytometry</i> , 2017, 92, 218-227.	0.7	44
119	Maturation-associated gene expression profiles along normal human bone marrow monoipoiesis. <i>British Journal of Haematology</i> , 2017, 176, 464-474.	1.2	9
120	Advances in the Classification and Treatment of Mastocytosis: Current Status and Outlook toward the Future. <i>Cancer Research</i> , 2017, 77, 1261-1270.	0.4	210
121	Host virus and pneumococcus-specific immune responses in high-count monoclonal B-cell lymphocytosis and chronic lymphocytic leukemia: implications for disease progression. <i>Haematologica</i> , 2017, 102, 1238-1246.	1.7	9
122	Detailed immunophenotyping of B-cell precursors in regenerating bone marrow of acute lymphoblastic leukaemia patients: implications for minimal residual disease detection. <i>British Journal of Haematology</i> , 2017, 178, 257-266.	1.2	37
123	Standardized flow cytometry for highly sensitive MRD measurements in B-cell acute lymphoblastic leukemia. <i>Blood</i> , 2017, 129, 347-357.	0.6	323
124	Guidelines for diagnosis, prevention and management of central nervous system involvement in diffuse large B-cell lymphoma patients by the Spanish Lymphoma Group (GELTAMO). <i>Haematologica</i> , 2017, 102, 235-245.	1.7	40
125	Immunophenotypic analysis of erythroid dysplasia in myelodysplastic syndromes. A report from the IMDSFlow working group. <i>Haematologica</i> , 2017, 102, 308-319.	1.7	74
126	Proposed Terminology and Classification of Pre-Malignant Neoplastic Conditions: A Consensus Proposal. <i>EBioMedicine</i> , 2017, 26, 17-24.	2.7	24



#	ARTICLE	IF	CITATIONS
127	Diagnostic screening of paroxysmal nocturnal hemoglobinuria: Prospective multicentric evaluation of the current medical indications. <i>Cytometry Part B - Clinical Cytometry</i> , 2017, 92, 361-370.	0.7	19
128	Prognostic impact of a novel gene expression profile classifier for the discrimination between metastatic and non-metastatic primary colorectal cancer tumors. <i>Oncotarget</i> , 2017, 8, 107685-107700.	0.8	9
129	Depth of Response in Multiple Myeloma: A Pooled Analysis of Three PETHEMA/GEM Clinical Trials. <i>Journal of Clinical Oncology</i> , 2017, 35, 2900-2910.	0.8	248
130	Impact of Next-Generation Flow (NGF) Minimal Residual Disease (MRD) Monitoring in Multiple Myeloma (MM): Results from the Pethema/GEM2012 Trial. <i>Blood</i> , 2017, 130, 905-905.	0.6	18
131	Imatinib in systemic mastocytosis: a phase IV clinical trial in patients lacking exon 17 <i>KIT</i> mutations and review of the literature. <i>Oncotarget</i> , 2017, 8, 68950-68963.	0.8	83
132	A systematic approach for peptide characterization of B-cell receptor in chronic lymphocytic leukemia cells. <i>Oncotarget</i> , 2017, 8, 42836-42846.	0.8	7
133	Blastic plasmacytoid dendritic cell neoplasm frequently shows occult central nervous system involvement at diagnosis and benefits from intrathecal therapy. <i>Oncotarget</i> , 2016, 7, 10174-10181.	0.8	65
134	The myeloma stem cell concept, revisited: from phenomenology to operational terms. <i>Haematologica</i> , 2016, 101, 1451-1459.	1.7	55
135	Phenotypic and genomic analysis of multiple myeloma minimal residual disease tumor cells: a new model to understand chemoresistance. <i>Blood</i> , 2016, 127, 1896-1906.	0.6	81
136	Minimal residual disease monitoring and immune profiling in multiple myeloma in elderly patients. <i>Blood</i> , 2016, 127, 3165-3174.	0.6	129
137	<i>KIT</i> D816V mutated bone marrow mesenchymal stem cells in indolent systemic mastocytosis are associated with disease progression. <i>Blood</i> , 2016, 127, 761-768.	0.6	33
138	Immunophenotype of normal vs. myeloma plasma cells: Toward antibody panel specifications for MRD detection in multiple myeloma. <i>Cytometry Part B - Clinical Cytometry</i> , 2016, 90, 61-72.	0.7	177
139	Utility of CD54, CD229, and CD319 for the identification of plasma cells in patients with clonal plasma cell diseases. <i>Cytometry Part B - Clinical Cytometry</i> , 2016, 90, 91-100.	0.7	47
140	Phenotypic, transcriptomic, and genomic features of clonal plasma cells in light-chain amyloidosis. <i>Blood</i> , 2016, 127, 3035-3039.	0.6	34
141	International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. <i>Lancet Oncology</i> , The, 2016, 17, e328-e346.	5.1	1,866
142	Expression profile of novel cell surface molecules on different subsets of human peripheral blood antigen-presenting cells. <i>Clinical and Translational Immunology</i> , 2016, 5, e100.	1.7	19
143	Minimal residual disease evaluation by flow cytometry is a complementary tool to cytogenetics for treatment decisions in acute myeloid leukaemia. <i>Leukemia Research</i> , 2016, 40, 1-9.	0.4	29
144	Cutaneous manifestations in patients with mastocytosis: Consensus report of the European Competence Network on Mastocytosis; the American Academy of Allergy, Asthma & Immunology; and the European Academy of Allergology and Clinical Immunology. <i>Journal of Allergy and Clinical Immunology</i> , 2016, 137, 35-45.	1.5	289

#	ARTICLE	IF	CITATIONS
145	Tumor infiltrating immune cells in gliomas and meningiomas. <i>Brain, Behavior, and Immunity</i> , 2016, 53, 1-15.	2.0	228
146	Clinical, immunophenotypic, and molecular characteristics of well-differentiated systemic mastocytosis. <i>Journal of Allergy and Clinical Immunology</i> , 2016, 137, 168-178.e1.	1.5	72
147	Consensus guidelines for myeloma minimal residual disease sample staining and data acquisition. <i>Cytometry Part B - Clinical Cytometry</i> , 2016, 90, 26-30.	0.7	108
148	Genomic characterization of liver metastases from colorectal cancer patients. <i>Oncotarget</i> , 2016, 7, 72908-72922.	0.8	83
149	Altered neutrophil immunophenotypes in childhood B-cell precursor acute lymphoblastic leukemia. <i>Oncotarget</i> , 2016, 7, 24664-24676.	0.8	8
150	The cellular origin and malignant transformation of Waldenström macroglobulinemia. <i>Blood</i> , 2015, 125, 2370-2380.	0.6	80
151	Identification and characterization of the gene expression profiles for protein coding and non-coding RNAs of pancreatic ductal adenocarcinomas. <i>Oncotarget</i> , 2015, 6, 19070-19086.	0.8	15
152	Genetic/molecular alterations of meningiomas and the signaling pathways targeted. <i>Oncotarget</i> , 2015, 6, 10671-10688.	0.8	58
153	Minimal residual disease diagnostics in acute lymphoblastic leukemia: need for sensitive, fast, and standardized technologies. <i>Blood</i> , 2015, 125, 3996-4009.	0.6	410
154	The immunophenotype of mast cells and its utility in the diagnostic work-up of systemic mastocytosis. <i>Journal of Leukocyte Biology</i> , 2015, 97, 49-59.	1.5	47
155	Quality assessment program for uroflow protocols: Summary results of four-year (2010-2013) quality assurance rounds. <i>Cytometry Part A: the Journal of the International Society for Analytical Cytology</i> , 2015, 87, 145-156.	1.1	144
156	Detection of the KIT D816V mutation in peripheral blood of systemic mastocytosis: diagnostic implications. <i>Modern Pathology</i> , 2015, 28, 1138-1149.	2.9	88
157	High-throughput phage-display screening in array format. <i>Enzyme and Microbial Technology</i> , 2015, 79-80, 34-41.	1.6	1
158	Molecular and Genomic Alterations in Glioblastoma Multiforme. <i>American Journal of Pathology</i> , 2015, 185, 1820-1833.	1.9	141
159	New criteria for response assessment: role of minimal residual disease in multiple myeloma. <i>Blood</i> , 2015, 125, 3059-3068.	0.6	256
160	Ex vivo identification and characterization of a population of CD13 <sup>high</sup> CD105 <sup>+</sup> CD45 <sup>+</sup> mesenchymal stem cells in human bone marrow. <i>Stem Cell Research and Therapy</i> , 2015, 6, 169.	2.4	21
161	Integration of Proteomics and Transcriptomics Data Sets for the Analysis of a Lymphoma B-Cell Line in the Context of the Chromosome-Centric Human Proteome Project. <i>Journal of Proteome Research</i> , 2015, 14, 3530-3540.	1.8	16
162	Complex Measurements May Be Required to Establish the Prognostic Impact of Immunophenotypic Markers in AML. <i>American Journal of Clinical Pathology</i> , 2015, 144, 484-492.	0.4	13

#	ARTICLE	IF	CITATIONS
163	Post-Remission Treatment with Chemotherapy or Allogeneic Hematopoietic Stem Cell Transplantation (alloHSCT) of High-Risk (HR) Philadelphia Chromosome-Negative (Ph-neg) Adult Acute Lymphoblastic Leukemia (ALL) According to Minimal Residual Disease (MRD). Preliminary Results of the Pethema ALL-HR-11 Trial. <i>Blood</i> , 2015, 126, 1333-1333.	0.6	9
164	Next Generation Flow (NGF) for High Sensitive Detection of Minimal Residual Disease (MRD) in Multiple Myeloma (MM). <i>Blood</i> , 2015, 126, 367-367.	0.6	2
165	Next Generation Flow (NGF): A High Sensitive Technique to Detect Circulating Peripheral Blood (PB) Clonal Plasma Cells (cPC) in Patients with Newly Diagnosed of Plasma Cell Neoplasms (PCN). <i>Blood</i> , 2015, 126, 4180-4180.	0.6	4
166	Phenotypic profile of expanded NK cells in chronic lymphoproliferative disorders: a surrogate marker for NK-cell clonality. <i>Oncotarget</i> , 2015, 6, 42938-42951.	0.8	23
167	Survival analysis in hematologic malignancies: recommendations for clinicians. <i>Haematologica</i> , 2014, 99, 1410-1420.	1.7	103
168	Research update for articles published in EJC in 2012. <i>European Journal of Clinical Investigation</i> , 2014, 44, 1010-1023.	1.7	1
169	B-cell prolymphocytic leukemia: a specific subgroup of mantle cell lymphoma. <i>Blood</i> , 2014, 124, 412-419.	0.6	48
170	Immune reconstitution in patients with Fanconi anemia after allogeneic bone marrow transplantation. <i>Cytotherapy</i> , 2014, 16, 976-989.	0.3	9
171	Evaluation of homo- and hetero-functionally activated glass surfaces for optimized antibody arrays. <i>Analytical Biochemistry</i> , 2014, 450, 37-45.	1.1	24
172	Altered Interphase Fluorescence in Situ Hybridization Profiles of Chromosomes 4, 8q24, and 9q34 in Pancreatic Ductal Adenocarcinoma Are Associated with a Poorer Patient Outcome. <i>Journal of Molecular Diagnostics</i> , 2014, 16, 648-659.	1.2	3
173	Human IgE+ B cells are derived from T cellâ€‘dependent and T cellâ€‘independent pathways. <i>Journal of Allergy and Clinical Immunology</i> , 2014, 134, 688-697.e6.	1.5	79
174	Flow Cytometry in Mastocytosis. <i>Immunology and Allergy Clinics of North America</i> , 2014, 34, 297-313.	0.7	14
175	Nonaggressive systemic mastocytosis (SM) without skin lesions associated with insect-induced anaphylaxis shows unique features versus other indolent SM. <i>Journal of Allergy and Clinical Immunology</i> , 2014, 133, 520-528.e5.	1.5	118
176	Detection and outcome of occult leptomeningeal disease in diffuse large B-cell lymphoma and Burkitt lymphoma. <i>Haematologica</i> , 2014, 99, 1228-1235.	1.7	69
177	<sc>CD</sc>30 expression by bone marrow mast cells from different diagnostic variants of systemic mastocytosis. <i>Histopathology</i> , 2013, 63, 780-787.	1.6	77
178	Gene expression profile of highly purified bone marrow mast cells in systemic mastocytosis. <i>Journal of Allergy and Clinical Immunology</i> , 2013, 131, 1213-1224.e4.	1.5	30
179	Overview of clinical flow cytometry data analysis: recent advances and future challenges. <i>Trends in Biotechnology</i> , 2013, 31, 415-425.	4.9	119
180	International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) & European Competence Network on Mastocytosis (ECNM) consensus response criteria in advanced systemic mastocytosis. <i>Blood</i> , 2013, 121, 2393-2401.	0.6	122

#	ARTICLE	IF	CITATIONS
181	Detailed characterization of multiple myeloma circulating tumor cells shows unique phenotypic, cytogenetic, functional, and circadian distribution profile. <i>Blood</i> , 2013, 122, 3591-3598.	0.6	131
182	Analysis of the immune system of multiple myeloma patients achieving long-term disease control by multidimensional flow cytometry. <i>Haematologica</i> , 2013, 98, 79-86.	1.7	132
183	Contribution of Multiparameter Flow Cytometry Immunophenotyping to the Diagnostic Screening and Classification of Pediatric Cancer. <i>PLoS ONE</i> , 2013, 8, e55534.	1.1	48
184	Biomarker Discovery by Novel Sensors Based on Nanoproteomics Approaches. <i>Sensors</i> , 2012, 12, 2284-2308.	2.1	59
185	Complete Response After Imatinib Mesylate Therapy in a Patient With Well-Differentiated Systemic Mastocytosis. <i>Journal of Clinical Oncology</i> , 2012, 30, e126-e129.	0.8	59
186	Definitions, Criteria and Global Classification of Mast Cell Disorders with Special Reference to Mast Cell Activation Syndromes: A Consensus Proposal. <i>International Archives of Allergy and Immunology</i> , 2012, 157, 215-225.	0.9	513
187	Immunophenotypic Identification and Characterization of Tumor Cells and Infiltrating Cell Populations in Meningiomas. <i>American Journal of Pathology</i> , 2012, 181, 1749-1761.	1.9	66
188	Self-assembled Protein Arrays from an <i>Ornithodoros moubata</i> Salivary Gland Expression Library. <i>Journal of Proteome Research</i> , 2012, 11, 5972-5982.	1.8	37
189	Amplified and Homozygously Deleted Genes in Glioblastoma: Impact on Gene Expression Levels. <i>PLoS ONE</i> , 2012, 7, e46088.	1.1	38
190	Nanotechniques in proteomics: Protein microarrays and novel detection platforms. <i>European Journal of Pharmaceutical Sciences</i> , 2012, 45, 499-506.	1.9	75
191	Comparison of Immunofixation, Serum Free Light Chain, and Immunophenotyping for Response Evaluation and Prognostication in Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2011, 29, 1627-1633.	0.8	202
192	Indolent systemic mastocytosis without skin involvement vs. isolated bone marrow mastocytosis. <i>Haematologica</i> , 2011, 96, e26-e26.	1.7	4
193	CD117 expression in gammopathies is associated with an altered maturation of the myeloid and lymphoid hematopoietic cell compartments and favorable disease features. <i>Haematologica</i> , 2011, 96, 328-332.	1.7	46
194	Cytogenetic heterogeneity of pancreatic ductal adenocarcinomas: identification of intratumoral pathways of clonal evolution. <i>Histopathology</i> , 2011, 58, 486-497.	1.6	7
195	Flow cytometry immunophenotyping of fine-needle aspiration specimens: utility in the diagnosis and classification of non-Hodgkin lymphomas. <i>Histopathology</i> , 2011, 58, 906-918.	1.6	59
196	New technologies in cancer. Protein microarrays for biomarker discovery. <i>Clinical and Translational Oncology</i> , 2011, 13, 156-161.	1.2	36
197	Cell cycle distribution of different cell compartments in normal versus reactive bone marrow: A frame of reference for the study of dysplastic hematopoiesis. <i>Cytometry Part B - Clinical Cytometry</i> , 2011, 80B, 354-361.	0.7	18
198	Association between Genetic Subgroups of Pancreatic Ductal Adenocarcinoma Defined by High Density 500 K SNP-Arrays and Tumor Histopathology. <i>PLoS ONE</i> , 2011, 6, e22315.	1.1	16

#	ARTICLE	IF	CITATIONS
199	Circulating human B and plasma cells. Age-associated changes in counts and detailed characterization of circulating normal CD138- and CD138+ plasma cells. <i>Haematologica</i> , 2010, 95, 1016-1020.	1.7	210
200	Intratumoral patterns of clonal evolution in gliomas. <i>Neurogenetics</i> , 2010, 11, 227-239.	0.7	23
201	Gene expression profiles of human glioblastomas are associated with both tumor cytogenetics and histopathology. <i>Neuro-Oncology</i> , 2010, 12, 991-1003.	0.6	45
202	Mast cells from different molecular and prognostic subtypes of systemic mastocytosis display distinct immunophenotypes. <i>Journal of Allergy and Clinical Immunology</i> , 2010, 125, 719-726.e4.	1.5	128
203	Multiparameter flow cytometry quantification of bone marrow plasma cells at diagnosis provides more prognostic information than morphological assessment in myeloma patients. <i>Haematologica</i> , 2009, 94, 1599-1602.	1.7	92
204	Prognosis in adult indolent systemic mastocytosis: A long-term study of the Spanish Network on Mastocytosis in a series of 145 patients. <i>Journal of Allergy and Clinical Immunology</i> , 2009, 124, 514-521.	1.5	252
205	Identification of Leptomeningeal Disease in Aggressive B-Cell Non-Hodgkin's Lymphoma: Improved Sensitivity of Flow Cytometry. <i>Journal of Clinical Oncology</i> , 2009, 27, 1462-1469.	0.8	189
206	Generation of flow cytometry data files with a potentially infinite number of dimensions. <i>Cytometry Part A: the Journal of the International Society for Analytical Cytology</i> , 2008, 73A, 834-846.	1.1	81
207	Prognostic Value of Immunophenotyping in Multiple Myeloma: A Study by the PETHEMA/GEM Cooperative Study Groups on Patients Uniformly Treated With High-Dose Therapy. <i>Journal of Clinical Oncology</i> , 2008, 26, 2737-2744.	0.8	193
208	Peripheral Blood Dendritic Cell Subsets from Patients with Monoclonal Gammopathies Show an Abnormal Distribution and Are Functionally Impaired. <i>Oncologist</i> , 2008, 13, 82-92.	1.9	21
209	Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation. <i>Blood</i> , 2008, 112, 4017-4023.	0.6	425
210	Recent advances in the understanding of mastocytosis: the role of KIT mutations. <i>British Journal of Haematology</i> , 2007, 138, 12-30.	1.2	205
211	KIT mutation in mast cells and other bone marrow hematopoietic cell lineages in systemic mast cell disorders: a prospective study of the Spanish Network on Mastocytosis (REMA) in a series of 113 patients. <i>Blood</i> , 2006, 108, 2366-2372.	0.6	447
212	Accurate apoptosis measurement requires quantification of loss of expression of surface antigens and cell fragmentation. <i>Cytometry Part A: the Journal of the International Society for Analytical Cytology</i> , 2006, 69A, 240-248.	1.1	5
213	Minimal residual disease monitoring in multiple myeloma: a comparison between allelic-specific oligonucleotide real-time quantitative polymerase chain reaction and flow cytometry. <i>Haematologica</i> , 2005, 90, 1365-72.	1.7	135
214	Immunophenotypic analysis of mast cells in mastocytosis: When and how to do it. Proposals of the Spanish Network on Mastocytosis (REMA). , 2004, 58B, 1-8.		130
215	Neoplasias of dendritic cells: are they the counterpart of one or more cell lineages?. <i>Laboratory Hematology: Official Publication of the International Society for Laboratory Hematology</i> , 2004, 10, 171.	1.2	1
216	TCR $\beta$ <sup>+</sup> /CD4 <sup>+</sup> Large Granular Lymphocytosis. <i>American Journal of Pathology</i> , 2003, 163, 763-771.	1.9	104

#	ARTICLE	IF	CITATIONS
217	Immunophenotype and TCR-V $\beta$ 2 repertoire of peripheral blood T-cells in acute infectious mononucleosis. <i>Blood Cells, Molecules, and Diseases</i> , 2003, 30, 1-12.	0.6	33
218	Utility of flow cytometry immunophenotyping and DNA ploidy studies for diagnosis and characterization of blood involvement in CD4+ S $\alpha$ zary's syndrome. <i>Haematologica</i> , 2003, 88, 874-87.	1.7	30
219	Immunophenotypic evaluation of the plasma cell compartment in multiple myeloma: a tool for comparing the efficacy of different treatment strategies and predicting outcome. <i>Blood</i> , 2002, 99, 1853-1856.	0.6	140
220	Immunophenotypic Analysis of the TCR-V $\beta$ 2 Repertoire in 98 Persistent Expansions of CD3+/TCR- $\beta$ 2+ Large Granular Lymphocytes. <i>American Journal of Pathology</i> , 2001, 159, 1861-1868.	1.9	113
221	Early immunophenotypical evaluation of minimal residual disease in acute myeloid leukemia identifies different patient risk groups and may contribute to postinduction treatment stratification. <i>Blood</i> , 2001, 98, 1746-1751.	0.6	316
222	Evaluation of a CD61 MoAb method for enumeration of platelets in thrombocytopenic patients and its impact on the transfusion decision-making process. <i>Transfusion</i> , 2001, 41, 1212-1216.	0.8	17
223	Gains of chromosome 22 by fluorescence in situ hybridization in the context of an hyperdiploid karyotype are associated with aggressive clinical features in meningioma patients. <i>Cancer</i> , 2001, 92, 377-385.	2.0	34
224	Utility of flow cytometric analysis of mast cells in the diagnosis and classification of adult mastocytosis. <i>Leukemia Research</i> , 2001, 25, 563-570.	0.4	124
225	Two new 3'PML Breakpoints in t(15;17)(q22;q21)-positive acute promyelocytic leukemia. , 2000, 27, 35-43.		19
226	Flow cytometric detection of intracellular myeloperoxidase, CD3 and CD79a. <i>Journal of Immunological Methods</i> , 2000, 242, 53-65.	0.6	51
227	Two new 3' PML Breakpoints in t(15;17)(q22;q21)-positive acute promyelocytic leukemia. <i>Genes Chromosomes and Cancer</i> , 2000, 27, 35-43.	1.5	3
228	Immunophenotype of Bone Marrow Mast Cells in Indolent Systemic Mast Cell Disease in Adults. <i>Leukemia and Lymphoma</i> , 1999, 35, 227-235.	0.6	42
229	Chronic Alcoholism Is Associated With an Imbalanced Production of Th-1/Th-2 Cytokines by Peripheral Blood T Cells. <i>Alcoholism: Clinical and Experimental Research</i> , 1999, 23, 1306-1311.	1.4	76
230	Report on the first Latin American consensus conference for flow cytometric immunophenotyping of leukemia. <i>Cytometry</i> , 1998, 34, 39-42.	1.8	21
231	Human bone marrow mast cells from indolent systemic mast cell disease constitutively express increased amounts of the CD63 protein on their surface. , 1998, 34, 223-228.		34
232	Expression of the c-kit (CD117) Molecule in Normal and Malignant Hematopoiesis. <i>Leukemia and Lymphoma</i> , 1998, 30, 459-466.	0.6	113
233	Indolent Systemic Mast Cell Disease in Adults: Immunophenotypic Characterization of Bone Marrow Mast Cells and Its Diagnostic Implications. <i>Blood</i> , 1998, 91, 2731-2736.	0.6	232
234	Abnormalities of Peripheral Blood T Lymphocytes and Natural Killer Cells in Alcoholic Hepatitis Persist after a 3-Month Withdrawal Period. <i>Alcoholism: Clinical and Experimental Research</i> , 1997, 21, 672-676.	1.4	28

#	ARTICLE	IF	CITATIONS
235	Alterations in Tumor Necrosis Factor-alpha, Interferon-gamma, and Interleukin-6 Production by Natural Killer Cell-Enriched Peripheral Blood Mononuclear Cells in Chronic Alcoholism: Relationship with Liver Disease and Ethanol Intake. <i>Alcoholism: Clinical and Experimental Research</i> , 1997, 21, 1226-1231.	1.4	39
236	Effect of Ethanol Consumption on Adult Rat Liver Mitochondrial Populations Analyzed by Flow Cytometry. <i>Alcoholism: Clinical and Experimental Research</i> , 1995, 19, 1327-1330.	1.4	9
237	Long-term treatment results for acute megakaryoblastic leukaemia patients: a multicentre study. <i>British Journal of Haematology</i> , 1992, 82, 671-675.	1.2	22
238	Discrepancies Between Morphologic, Cytochemical, and Immunologic Characteristics in Acute Myeloblastic Leukemia. <i>American Journal of Clinical Pathology</i> , 1987, 88, 38-42.	0.4	17